We are live on ! Find out more
NCM

NEXTBio Capital Management Portfolio holdings

AUM $217M
This Fund
S&P 500
This Quarter Est. Return
+26.16%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$217M
AUM Growth
+$2.03M
Cap. Flow
-$26.9M
Cap. Flow %
-12.39%
Top 10 Hldgs %
77.7%
Holding
27
New
3
Increased
7
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
GPCR icon
Structure Therapeutics
GPCR
+$7.93M
2
STTK icon
Shattuck Labs
STTK
+$3.6M
3
PHVS icon
Pharvaris
PHVS
+$3.27M
4
IVA
Inventiva
IVA
+$2.18M
5
LBRX
LB Pharmaceuticals
LBRX
+$2M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$31.9M
2
CMPX icon
Compass Therapeutics
CMPX
+$4.49M
3
OCS icon
Oculis Holding
OCS
+$3.98M
4
KALV
KalVista Pharmaceuticals
KALV
+$2.65M
5
CMPS
Compass Pathways
CMPS
+$2.49M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SMMT icon
26
Summit Therapeutics
SMMT
$11B
– –
-89,717
Closed -$1.7M
TERN
27
DELISTED
Terns Pharmaceuticals
TERN
– –
-604,534
Closed -$31.9M
1
2

Similar funds

HIMS
Hager Investment Management Services New London, New Hampshire $217M AUM 56.89% 1-Year Est. Return
CWM
Carolina Wealth Management Greenville, North Carolina $217M AUM
PP
Pearl Planning Dexter, Michigan $217M AUM
WWM
Wolff Wiese Magana Carslbad, California $217M AUM 47.64% 1-Year Est. Return
CA
Corrado Advisors Ramsey, New Jersey $217M AUM 26.96% 1-Year Est. Return
ECM
English Capital Management Bloomfield Hills, Michigan $217M AUM 37.8% 1-Year Est. Return
RFM
RPD Fund Management New York $218M AUM 48.33% 1-Year Est. Return
DCM
Delta Capital Management Red Bank, New Jersey $217M AUM 67.79% 1-Year Est. Return

NEXTBio Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, NEXTBio Capital Management held 27 positions worth $217M, up 0.94% from $215M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

NEXTBio Capital Management withdrew a net $26.9M in Q2 2026, closing 5 positions and reducing 5 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $31.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, NEXTBio Capital Management opened a new position in Pharvaris worth $3.74M.

  • NEXTBio Capital Management's largest Q2 2026 buy was Pharvaris: 108,055 shares worth $3.74M.
  • NEXTBio Capital Management added most to Structure Therapeutics in Q2 2026, an estimated $7.93M increase.
  • NEXTBio Capital Management's biggest Q2 2026 reduction was Compass Pathways, cutting an estimated $2.49M.
  • NEXTBio Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $31.9M.
  • NEXTBio Capital Management's ten largest holdings make up 78% of its $217M portfolio in Q2 2026.
  • NEXTBio Capital Management opened 3 new positions and closed 5 in Q2 2026.
  • NEXTBio Capital Management's portfolio value rose 0.94% quarter-over-quarter to $217M.

Based on NEXTBio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.